Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAccess to the study page now results in a 403 Forbidden error, replacing the previous study record content. The error page includes the 403 message and site chrome, indicating the record is currently inaccessible.SummaryDifference18%

- Check35 days agoChange DetectedThe page shows a revision update from v3.6.5 to v3.6.6, indicating a minor platform update rather than a change to the study details.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page footer now displays Revision: v3.6.5 instead of v3.6.4, indicating an internal site update without changing the trial details.SummaryDifference0.1%

- Check71 days agoChange DetectedA new site revision label (v3.6.4) was added, signaling a deployment update to the platform rather than a change to the study information.SummaryDifference0.1%

- Check93 days agoChange DetectedFooter revision updated to Revision: v3.6.3 replacing the previous Revision: v3.6.2. This indicates a deployment/version bump with no changes to study details.SummaryDifference0.1%

- Check100 days agoChange DetectedThe footer revision was updated from v3.6.0 to v3.6.2, indicating a minor build update. No content or functionality changes are introduced on the study details page.SummaryDifference0.1%

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.